Skip to content

Advertisement

  • Research
  • Open Access

Repair of astrocytes, blood vessels, and myelin in the injured brain: possible roles of blood monocytes

Molecular Brain20136:28

https://doi.org/10.1186/1756-6606-6-28

©  Jeong et al.; licensee BioMed Central Ltd. 2013

  • Received: 21 March 2013
  • Accepted: 1 May 2013
  • Published:

Abstract

Inflammation in injured tissue has both repair functions and cytotoxic consequences. However, the issue of whether brain inflammation has a repair function has received little attention. Previously, we demonstrated monocyte infiltration and death of neurons and resident microglia in LPS-injected brains (Glia. 2007. 55:1577; Glia. 2008. 56:1039). Here, we found that astrocytes, oligodendrocytes, myelin, and endothelial cells disappeared in the damage core within 1–3 d and then re-appeared at 7–14 d, providing evidence of repair of the brain microenvironment. Since round Iba-1+/CD45+ monocytes infiltrated before the repair, we examined whether these cells were involved in the repair process. Analysis of mRNA expression profiles showed significant upregulation of repair/resolution-related genes, whereas proinflammatory-related genes were barely detectable at 3 d, a time when monocytes filled injury sites. Moreover, Iba-1+/CD45+ cells highly expressed phagocytic activity markers (e.g., the mannose receptors, CD68 and LAMP2), but not proinflammatory mediators (e.g., iNOS and IL1β). In addition, the distribution of round Iba-1+/CD45+ cells was spatially and temporally correlated with astrocyte recovery. We further found that monocytes in culture attracted astrocytes by releasing soluble factor(s). Together, these results suggest that brain inflammation mediated by monocytes functions to repair the microenvironment of the injured brain.

Keywords

  • Brain inflammation
  • Repair
  • Brain microenvironment

Background

Brain inflammation accompanied by brain injury has been a focus of research efforts because of its possible roles in the onset and progression of a number of neurodegenerative diseases. However, most brain inflammation studies have focused on neurons, and little information on how brain inflammation affects other brain cells, including astrocytes and oligodendrocytes, is available. Astrocytes function to maintain the homeostasis of the brain microenvironment by taking up potassium, glutamate, and water from the extracellular space, and supplying nutrients and growth factors to neurons (for review, see[1]). Oligodendrocytes myelinate axons, allowing for rapid propagation of action potentials to axon terminals. Therefore, it is important to know how these cells respond to brain injury.

Studies of systemic inflammation showed that inflammation has dual functions: a cytotoxic function to kill infected microbes and a repair function to regenerate damaged tissues[2, 3]. In the presence of proinflammatory stimulators such as IFN-γ, monocytes/macrophages are classically activated and protect the tissue from infection by producing cytotoxic inflammatory molecules[4, 5]. On the other hand, in the presence of IL-4 and IL-13, monocytes/macrophages are alternatively activated, and produce several molecules that are involved in anti-inflammation and repair/regeneration[6–9]. Therefore, in myocardial injury, monocytes/macrophages rapidly remove cell debris and lead to myofibroblast infiltration and collagen deposition through production of high levels of TGF-β and VEGF-A[8]. In injured skin, macrophage depletion causes delays in healing processes[10, 11].

Previously, we reported that in lipopolysaccharide (LPS)- or ATP-injected brain and contusion-induced spinal cord, resident microglia as well as neurons die in the damage core and monocytes appear and fill the damage core[12–15]. In the ischemic brain, infiltration of blood monocytes has been reported[16, 17]. However, it is not clear how monocytes contribute to brain inflammation and what occurs after monocytes infiltrate into the injured brain.

In the present study, we examined how astrocytes, oligodendrocytes, and endothelial cells respond to damage in the LPS-injected substantia nigra (SN), a Parkinson’s disease-related brain area where LPS induces significant damage[13]. We also examined the roles of infiltrating monocytes in the injured brain. The results of this study showed that damage to astrocytes, oligodendrocytes, and endothelial cells peaked at approximately 3 d. However, these cells recovered 7–14 d after infiltration from the blood of round Iba-1+/CD45+ monocytes. Importantly, these monocytes expressed repair/regeneration-related genes, suggesting that they may function to repair the damaged brain.

Results

Recovery of the damaged microenvironment in the injured brain

Since most studies of brain injury have focused on neuronal damage, knowledge is limited on how other brain cells behave in the injured brain. In the present study, we first examined the time-dependent responses of brain cells, including astrocytes, endothelial cells, oligodendrocytes (by examining myelin) and inflammatory cells, in the injured brain. To achieve this, LPS (5 μg in 2 μl PBS) was injected into the substantia nigra pars compacta (SNpc); this region was chosen based on our previous observation that LPS induces significant damage to the SNpc but not to the cortex[13].

In the intact brain, the density of GFAP+ astrocytes (arrows in Figure 1Ab) differs among regions; within the SN, it is low in the SNpc and high in the substantia nigra pars reticulata (SNr) (Figure 1Aa-c). LPS injection into the SNpc induced the death of astrocytes within 12 h (Figure 1Ag, h), as we and others have previously reported[13, 18]. At 1–3 d, GFAP+ astrocyte-empty areas were significantly expanded (Figure 1Aj-o). In the SNr, the number of astrocytes was reduced on day 1 (Figure 1Al), and these cells almost disappeared by day 3 (Figure 1Ao). In response to PBS-injection, astrocytes became activated − the number of astrocyte processes increased and the processes became longer and thicker (arrow in Figure 1Ae) − but death did not occur (Figure 1Ad-f). Interestingly, however, the impaired astrocytes recovered between 7 and 14 d, although they exhibited a highly activated morphology (Figure 1Ar, t, u). At 2 mo, astrocytes filled the damaged areas almost completely (Figure 1Av), although these cells were still activated (arrows in Figure 1Aw, x).
Figure 1
Figure 1

Impaired astrocytes were subsequently recovered in the LPS-injected SNpc. (A-D) LPS (5 μg/2 μl) was injected into the SNpc. Sections obtained at the indicated times after LPS injection were labeled with antibodies specific for GFAP (A), S100β (B), EAAT1 (C), and Kir 4.1 (D), and visualized with peroxidase-conjugated secondary antibodies. Lower panels (SNpc and SNr) are higher magnification images of boxed areas (SNpc and SNr) in upper panels. Arrows indicate GFAP+ (A), S100β+ (B) EAAT1+ (C) and Kir4.1+ (D) cells. Contralateral (Contra) sides of LPS-injected animals and PBS-injected animals were used as controls. Asterisks (*) indicate injection sites. Scale bars, 1 mm (upper panels in A), 200 μm (upper panels in C-E), 50 μm (lower panels in A), 20 μm (lower panels in C-E). (E-H) GFAP-, S100β-, EAAT1-, and Kir 4.1-negative areas in every sixth brain section were quantified using Axiovision image analysis software, as described in “Materials and Methods”. Values are means ± SEMs of at least three samples (*p < 0.01; **p < 0.001; Student’s t-test). Three or more animals were used for each time point. All data presented in this study are representative of at least three independent experiments unless indicated.

The disappearance and reappearance of GFAP+ astrocytes were not merely due to reduced GFAP immunoreactivity since other markers of astrocytes in addition to GFAP, including S100β (Ca2+-binding protein), EAAT1 (GLAST, excitatory amino acid transporter 1) and Kir4.1 (potassium channel), also disappeared at 3 d (Figure 1B-D) and reappeared at 14 d (arrows in Figure 1B-D). The areas in which each marker was absent were measured and plotted (Figure 1E-H). Using Nissl staining, we verified the death of astrocytes at 1 d (Additional file1: Figure S1).

We next examined oligodendrocytes and myelin. CC-1+ oligodendrocytes were injured at 3 d and gradually recovered beginning on day 7 (Figure 2A). Similarly, the decrease in Eriochrome Cyanine RC (ECRC)-stained myelin also reached a peak at 3–7 d, but gradually recovered at 14 d and 2 mo (Figure 2B, D). Blood vessels with SMI 71+ endothelial cells disappeared in the injection core at 3 d after LPS injection, but reappeared at 14 d, and seemed to be almost intact at 2 mo (Figure 2C, D). Interestingly, the neuron-damage area detected by MAP2+ dendrites reached a peak at 3 d and was maintained and/or slightly decreased at 7 d before decreasing gradually at later time points (14 d and 2 mo) (Figure 3A, B). TH-positivity also showed a similar pattern. In the contralateral (contra) side and in PBS-injected controls, TH+ dopaminergic neuronal cell bodies were detectable (Figure 3C, white arrows), but both TH+ dopaminergic neuronal cell bodies and processes were injured at 3 d after LPS injection. Notably, however, only processes (white arrowheads), but not cell bodies, reappeared at 14 d and 2 mo (Figure 3C). These results suggest that brain microenvironmental damage (damage to astrocytes, oligodendrocytes, myelin, blood vessels, and neurites) actively recovers in the injured brain.
Figure 2
Figure 2

Recovery of impaired oligodendrocytes, myelin, and endothelial cells in LPS-injected SNpc. (A, C) At the indicated times after LPS injection, sections were labeled with antibodies specific for markers of oligodendrocytes (CC1) and endothelial cells (SMI 71). (B) For myelin staining, sections were stained with ECRC. (A-C) Lower panels are higher magnification images of boxed areas in upper panels. Contralateral (Contra) sides of LPS-injected animals and PBS-injected animals were used as controls. (D) ECRC- and SMI 71-negative areas were quantified at the indicated times. Values are means ± SEMs of more than three samples (*p < 0.01; **p < 0.001; Student’s t-test). Asterisks (*) indicate drug injection sites. Scale bars, 1 mm (upper panels in A, B), 200 μm (upper panels in C), 100 μm (lower panels in B, C), and 50 μm (lower panels in A).

Figure 3
Figure 3

Recovery of impaired neurites in LPS-injected SNpc. (A, C) At the indicated times after LPS injection, sections were labeled with antibodies specific for markers of MAP2 (A) and tyrosine hydroxylase (TH) (C). Lower panels are higher magnification images of boxed areas in upper panels. Arrows in lower panels in (C) indicate TH+ cell bodies. (B) MAP2-negative areas at 3 and 14 d after LPS injection were quantified. Values are means ± SEMs of more than three samples (*p < 0.01; Student’s t-test). Asterisks (*) indicate injection sites. (C) In contralateral (contra) sides and PBS-injected brains, TH+ dopaminergic neuronal cell bodies were detectable (white arrows), but TH+ dopaminergic neuronal cell bodies and processes were injured at 3 d after LPS injection. At 14 d and 2 mo, only processes reappeared (white arrowheads). Scale bars, 1 mm (upper panels in A, C), and 100 μm (lower panels in A, C).

Astrocytes and oligodendrocytes proliferate and migrate toward the damage

We further examined whether the impaired astrocytes could be recovered by cell proliferation. Cells expressing Ki-67 (a cell cycle protein used as a proliferation marker) significantly increased from 3 d (Figure 4A), while Ki-67+ cells were barely detectable in intact SNpc and at 1 d after LPS injection (Figure 4A). In double-labeling experiments, proliferating Ki67+ cells were merged with GFAP+ and/or vimentin+ astrocytes (Figure 4B). In addition, Ki67 immunoreactivity was found in Olig2+ cells, which are considered progenitor cells of oligodendrocytes and astrocytes, as well as in reactive astrocytes[19, 20] (Figure 4B). Interestingly, Olig2 was detected in either the nucleus (arrows) or cytosol (arrowheads) of GFAP+ or vimentin+ astrocytes and CC-1+ oligodendrocytes 7 d after LPS injection (Figure 4C). These findings suggest that astrocytes and oligodendrocytes proliferate and fill in astrocyte- and oligodendrocyte-deficient regions in the LPS-injected SNpc.
Figure 4
Figure 4

Ki-67 immunoreactivity was found in astrocytes and oligodendrocytes in LPS-injected SNpc. (A) Brain sections were prepared at the indicated times after LPS-, and PBS-injection and stained with antibodies specific for Ki-67. Lower panels are higher magnification of boxed areas in upper panels. In intact contralateral (contra) sides and sections from PBS-injected brains, some Ki67+ cells were detectable (black arrows). Dotted lines at 3 and 14 d show areas where the number of Ki67+ cells dramatically increased (whiter arrows). Asterisks (*) indicate injection sites. (B) Sections obtained at 3 d were double-labeled with combinations of Ki-67/GFAP, Ki-67/Vimentin, and Ki67/Olig2 antibodies. Nuclei were labeled with DAPI. Arrows indicate cells co-labeled with Ki67 and each cellular marker. (C) Sections obtained at 7 d were double-labeled with combinations of Olig2/Vimentin and Olig2/CC-1 antibodies. Arrowheads and arrows indicate cells where Olig2 was found in the cytosol and nuclei, respectively. Scale bars, 200 μm (upper panels in A), 50 μm (lower panels in A), and 20 μm (B, C).

Possible involvement of brain inflammation in repair of damaged microenvironment of the brain

Because an important role of inflammation is to repair damaged tissue[8, 10] we examined whether brain inflammation could contribute to the repair of damage to the brain microenvironment. Previously, we reported that ramified Iba-1+ resident microglia died in injured brain and spinal cord, and that round Iba-1+ monocytes infiltrated into these tissues[12–15]. In this study, we found that in LPS-injected brain, the number of round Iba-1+ cells was markedly increased at 3 d, but subsequently decreased between 3 and 7 d (Figure 5A, B). In the SNpc, the decrease in the number of round Iba-1+ cells at 7 d appeared to be due to the death of a portion of these cells, since some round Iba-1+ cells were positive in TUNEL assays (lower panels ‘SNpc’ in Figure 5A, Additional file2: Figure S2). In SNr areas, Iba-1+ cells became ramified and highly expressed Iba-1 at 7 d (lower panels ‘SNr’ in Figure 5A, white arrows). In the intact brain, the density of Iba-1+ microglia was low in the SNpc and high in the SNr, as shown in the contralateral (Contra) side. We speculate that, during repair processes, more monocytes survive in the SNr and become resident microglia. Additionally, round Iba-1+ cells were not detectable in the PBS-injected brain (Figure 5A). Round CD45+ cells also appeared approximately 1 d after LPS injection whereas they were not detectable in intact and PBS-injected brains (Figure 5C). Particularly, these CD45+ cells were found around blood vessels (BV) with high densities (inset in Figure 5C lower panel ‘a’). The number of CD45+ cells and their recruited area also reached a maximum at 3 d, and then progressively decreased through to 7 d (Figure 5C). Double-labeling experiments additionally showed CD45 immunoreactivity in round Iba-1+ cells in the ipsilateral sides at 3 d (arrowheads in Figure 5D) but not in ramified Iba-1+ cells in the contralateral sides (arrows in Figure 5D). It has been reported that monocytes highly express Iba-1 and CD45, whereas resident microglia express Iba-1 but weakly and barely express CD45[12, 14, 21–24] (Table 1). Previously, we reported that labeled monocytes transplanted into the tail vein were found in the damage core in LPS-injected brains[12]. Therefore, based on these lines of evidence, we considered the round Iba-1+ and/or CD45+ cells as monocytes.
Figure 5
Figure 5

Appearance of Iba-1 + /CD45 + round cells in the LPS-injected SNpc. (A, C, D) Serial sections were obtained at the indicated times after LPS injection and labeled with Iba-1 (A), CD45 (C), and Iba-1/CD45 (D) antibodies. (A, C) Lower panels are higher magnification images of the boxed areas in the upper panels. (A) In intact contralateral (Contra) sides and PBS-injected brains, Iba-1+ cells were ramified (black arrows). In LPS-injected brain, round Iba-1+ cells were detectable at 1 d (white arrowheads), and the number of these cells increased at 3 d but decreased at 7 d. In SNr areas, Iba-1+ cells became ramified and highly expressed Iba-1 at 7 d (white arrows). (B) Iba-1+ cells at the indicated times after LPS injection were quantified. Values are means ± SEMs of more than three samples (*p < 0.001; Student’s t-test). (C) CD45+ cells were detectable at 1 d (white arrowheads), and the number of these cells increased at 3 d but decreased at 7 d. Some round CD45+ cells were found around blood vessels (BV) (inset ‘a’ in 3 d). (D) Brain sections obtained at 3 d were double-labeled with Iba-1 and CD45 antibodies, and visualized with Alexa Fluor 488- and 555-conjugated antibodies, respectively. Asterisks (*) indicate drug injection sites. Scale bars, 200 μm (upper panels in A, C), 50 μm (lower panels and the inset in A, C), and 20 μm (D).

Table 1

Primary antibodies used to detect microglia/monocytes

Name

Detectable cell types

References

CD11b

Brain microglia

[21]

Monocytes/macrophages

CD45

Monocytes (CD45high)

[14, 22, 24]

Microglia (CD45low)

Iba-1

Brain microglia

[12, 22, 23]

Monocytes/macrophages

Next, using a microarray, we examined mRNA expression patterns at times before (6 h) and after (3 d) infiltration of monocytes, respectively. At 6 h, mRNA expression of cytokines (IL1B, TNF, IL6), chemokines (CCL2, 3, 4, 7, CXCL 10 and 11), and transcription factors that regulate biosynthesis of cytokines and chemokines (IRF3, 7, and 9) significantly increased in the LPS-injected brain, but barely increased at 3 d (Figure 6A). In contrast, expression of genes associated with anti-inflammation (IL1RN, TGFB1, TGFBI, TGFBR1, IL10RA, IL10RB), phagocytosis (COLEC12, CD36, SCARB1, FCGR1), and wound healing (TGFB1, TGFBR2, PF4, VWF, COL3A1) were significantly increased at 3 d, but were barely elevated or decreased at 6 h after LPS injection (Figure 6B).
Figure 6
Figure 6

Microarray analysis of mRNA expression in the LPS-injected SNpc. mRNA expression profiles were compared in intact, and 3 h and 3 d after LPS-injected brain. For each microarray sample, brain tissue blocks (2 × 2 × 2 mm) were obtained from four animals, and total RNA was extracted as described in “Materials and Methods”. Relative mRNA levels of proinflammatory response-related genes (A) and repair/resolution-related genes (B) at 6 h and 3 d after LPS injection are shown as fold-changes normalized to that in the intact SNpc. Data shown are representative of two independent experiments.

We further analyzed gene expression by RT-PCR, focusing on the expression of two prominent inflammatory mediators, TNF-α and iNOS, and two markers of repair/resolution-related genes, mannose receptor (MR) and TGF-β1[7]. In the LPS-injected brain, expression of TNF-α and iNOS mRNA increased at times before infiltration of monocytes (3 and 12 h) compared with the PBS-injected brain, but was barely detectable at 1 d and thereafter (Figure 7A, B). On the other hand, mRNA expression of MR significantly increased from 1 d, and was maintained at an elevated level for up to 14 d (Figure 7A, B). TGF-β1 mRNA levels slightly increased in LPS-injected brain at 12 h-1 d after LPS injection, and remained elevated for up to 14 d (Figure 7A, B). Taken together, these results suggest that gene expression patterns in LPS-injected SN after monocyte infiltration show repair/resolution-related function rather than proinflammatory and/or neurotoxic function.
Figure 7
Figure 7

Iba-1 + /CD45 + round cells in LPS-injected SNpc were alternatively activated. (A, B) At the indicated times after LPS or PBS injection, brain tissue blocks (2 × 2 × 2 mm) were obtained, and the levels of TNF-α, iNOS, TGF-β1, and MR mRNA were analyzed by RT-PCR (A). Band intensities in (A) were analyzed and plotted (B). Intact (Int) SNpc was used as a control. (C-G) Sections were obtained at the indicated times after LPS injection and labeled with combinations of markers of microglia/monocytes (CD11b, CD45, Iba-1), neutrophils (MPO, myeloperoxidase), proinflammatory mediators (iNOS and IL-1beta), and alternative activation and phagocytosis (MR, CD68, and LAMP2). iNOS was detected in neutrophils and IL-1beta in ramified cells, respectively. All of MR, CD68, and LAMP2 were detected in round cells but not in ramified cells. Values in (B) are means ± SEMs of more than three samples (*p < 0.05; **, p < 0.001 for PBS vs. LPS; Student’s t-test). Data shown in (A and C-G) are representative of more than three samples. Intact SN region (Int) and PBS injection were used as controls. Scale bars, 20 μm (C-G).

Next, we used double-immunolabeling to examine whether monocytes expressed proinflammatory genes and repair/resolution-related genes in the injured brain. Depending on the sources of antibodies used to examine expression of proteins, microglia and/or monocytes were identified by staining for Iba-1, CD11b, or CD45 in these cells (Table 1). Expression of iNOS, a major inflammatory mediator, was detected in myeloperoxidase (MPO)+ neutrophils at 12 h to 1 d after LPS injection, but not in CD11b+ or CD45+ cells (Figure 7C), as we previously reported[12]. IL-1β expression was detected in ramified Iba-1+ cells at 3 h (Figure 7D). However, round CD45+ and Iba-1+ cells expressed neither iNOS nor IL-1β at 3–7 d (Figure 7D). Interestingly, most round CD45+ cells expressed mannose receptor (MR), which is known to play important roles in endocytosis/phagocytosis[25, 26] (Figure 7E). In addition, round but not ramified Iba-1+ cells highly expressed CD68, an indicator of lysosomal enzyme activity that is considered a marker of phagocytic activity[27] (Figure 7F). Round CD11b+ cells also highly expressed LAMP2 (Figure 7G), a lysosomal protein that participates in the fusion of lysosomes and phagosomes[28]. Since these monocytes have strong phagocytic activity, they may scavenge damaged cells and debris in the injured brain. These results suggest that monocytes may contribute to the recovery of impaired astrocytes in LPS-injected SNpc.

Possible spatial and temporal correlation between astrocytes and monocytes cells in the injured brain

Since recovery of the damaged microenvironment was detected in the damaged core filled with monocytes, we further examined whether correlation between repair of astrocytes and infiltration of monocytes in the injured brain. In results, we observed a correlation between the distribution of round monocytes and astrocytes: astrocytes expanded their territory as the area occupied by round Iba-1+/CD45+ cells decreased in a time-dependent manner (dotted lines in Figure 8A). In addition, astrocytes protruded their processes toward the damage core filled with monocytes at 7 d (arrows in Figure 8B, C). Furthermore, Vimentin, which positively regulates migration of cells including astrocytes[29, 30], was detectable in the protruded astrocyte processes near the damage core (arrows in Figure 8C, D), but not in astrocytes far from monocytes (arrowheads in Figure 8D).
Figure 8
Figure 8

Possible spatial and temporal correlation between astrocytes and round Iba-1 + cells in the injured brain. Brain sections (30 μm) were obtained at the indicated times after LPS injection. (A, C) Immediately adjacent serial sections were stained with GFAP, Iba-1, and Vimentin antibodies, respectively. Lower panels are higher magnification of boxed areas in upper panels. (B, D) Sections were double-labeled with GFAP/Iba-1 (B) or GFAP/Vimentin (D). Arrows indicate astrocyte processes protruded towards monocytes (B, C). Arrows and arrowheads indicate Vimentin+ astrocytes near monocytes and Vimentin- astrocytes far from monocytes, respectively (D). Dotted lines in (A, B, and D) indicate the borders where GFAP+ astrocytes were absent and/or Iba-1+ round monocytes were present. Data shown are representative of at least three independent experiments. In each experiment, three or more animals were used for each time point. Scale bars, 1 mm (A), 200 μm (upper panels in C), 100 μm (B, lower panels in C, and D), 50 μm (lower panels in A).

Next, we examined whether monocytes could encourage migration of astrocytes in culture. We measured migration ability of astrocytes using the PDMS device (Figure 9A). Astrocytes (Ast) and monocytes (Mo) were plated in each side of the groove. At 7 d after plating, astrocytes migrated toward monocytes when the direction of convective flow was from monocytes to astrocytes (Figure 9B left panel) but not when the direction was from astrocytes to monocytes (Figure 9B right panel). In addition, astrocytes did not move toward dead monocytes or toward media alone (data not shown). Taken together, these results suggest that monocytes in brain inflammation may contribute to recovery of damaged astrocytes by promoting astrocyte migration.
Figure 9
Figure 9

Monocytes facilitate astrocyte migration. Astrocytes and monocytes were co-cultured in the each compartment of PDMS devices (A) as described in “Materials and Methods”. (B) At 7 d after co-culture, astrocytes were visualized with calcein AM. Convective flow was generated by the difference in media volumes (250 vs. 300 μl) in the compartments in PDMS. The volume difference was maintained to day 7. Astrocytes migrated toward monocytes through the groove only when the convective flow was from monocytes to astrocytes (white arrows in B, left panel). The lower panels in (B) represent higher magnification of the indicated areas in the upper panels. Bars 200 μm (B upper panel); 50 μm (B lower panel).

Discussion

The results in this study showed that 1) astrocytes, oligodendrocytes, myelin, and endothelial cells recovered in the injured brain; 2) the recovery of these cells and myelin occurred after infiltration of Iba-1+/CD45+ monocytes into injury sites; 3) Iba-1+/CD45+ monocytes expressed repair-related inflammatory mediators, but not cytotoxic proinflammatory mediators; and 4) in vitro, monocytes secreted soluble factor(s) that recruited astrocytes toward them. On the basis of these findings, we suggest that monocytes may function to repair the injured brain.

Many studies on cultured microglia have reported that brain inflammation is neurotoxic. However, brain inflammation in vivo is quite different from the inflammation associated with microglia in culture[12–15, 31]. Simply, in the brain, several types of cells including microglia, astrocytes, neurons, and blood inflammatory cells, both positively and negatively contribute to inflammation. Microglia continuously survey brain damage, isolate damaged areas[14, 32], and recruit monocytes[33]. Astrocytes and/or neurons inhibit microglial activation[31, 34–37] and recruit monocytes[38]. Neutrophils produce cytotoxic inflammatory mediators in the brain[12, 17]. However, the roles of monocytes in the brain have not been clearly defined. Since monocytes/macrophages can be differentially activated (cytotoxic/classical vs. repair/alternative activation) depending on the stimuli, their roles also differ according to the activation conditions[7, 9]. The results presented here showed that monocytes in the LPS-injected brain exhibited repair-promoting rather than neurotoxic phenotypes. In microarray, RT-PCR, and immunohistochemistry analyses, repair/resolution-related genes/proteins such as phagocytic activation markers were highly expressed in the LPS-injected brain during the period when monocytes appeared, whereas cytotoxic proinflammatory mediators were barely expressed (Figures 6,7). Phagocytosis is an important process for the repair/regeneration of damaged tissue because damaged cells and debris may act as detrimental factors that lead to further injury or hinder regeneration[10]. In a multiple sclerosis animal model, stimulation of phagocytosis was shown to increase clearance of tissue debris, limit further destruction, and facilitate repair[39].

The question arising from the above considerations is how monocytes have a repair function instead of a neurotoxic function in the LPS-injected brain. There is a remote possibility that monocytes are activated by LPS since cerebrospinal fluid is exchanged about 11 times daily to maintain homeostasis of the brain in the adult rat brain[40]. Monocytes may be alternatively activated by phagocytosis of apoptotic cells. It has been reported that phagocytosis alters the phenotypes of monocytes from a proinflammatory to an anti-inflammatory phenotype[41]. Another possibility is that neutrophils that enter the brain prior to monocytes may induce alternative activation because neutrophils express IL-4, a strong inducer of alternative activation[6, 12, 42].

Next, we examined the issue of how astrocytes, oligodendrocytes, myelin, endothelial cells, and neurites reappeared in damaged areas. We detected Ki-67+ proliferating cells in the injured area, and these cells were merged with GFAP, Vimentin, and Olig2 (Figure 4), suggesting that astrocytes and oligodendrocytes proliferate and fill the damaged area. Interestingly, Olig2 immunoreactivity was located in the cytosol of GFAP+/Vimentin+ astrocytes and in the nuclei of CC-1+ oligodendrocytes (Figure 4C). It has been reported that Olig2 is expressed in progenitor cells of oligodendrocytes and astrocytes, as well as in reactive astrocytes in the injured brain[19, 20]. As we also showed in Figure 4C, it has been reported that Olig2 is located in the cytosol and nuclei of cells that are destined to become astrocytes and oligodendrocytes, respectively[43, 44]. Therefore, newly generated Ki67+/Olig2+ progenitors may replenish astrocytes and oligodendrocytes in the injured brain. It has been reported that monocytes express several chemokines, including IL-8, IP-10, CCL1, CCL2 (MCP-1), and CCL4[45, 46]. Monocytes also produce platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and hepatocyte growth factor (HGF)[47–49]. Therefore, monocytes may recruit and/or promote the proliferation of astrocytes and oligodendrocytes, and induce neurite outgrowth. These findings suggest that brain inflammation plays a role in repairing damaged brain tissue. Thus, we speculate that impairment of the repair function of inflammation due to aging or genetic mutations may result in delayed recovery from damage and neurodegeneration. In our microarray analysis, mRNA expression of several genes related to cell proliferation/migration and neurogenesis was upregulated at around the times when monocytes appeared in the brain (data not shown). Furthermore, we observed that, in culture, monocytes promote astrocyte migration toward them (Figure 9), suggesting that monocytes in the LPS-injected brain may attract astrocytes toward damaged areas for recovery. We expected that the recovery of oligodendrocytes might be similar to that of GFAP+ astrocytes, since they come to occupy the same microenvironment. In addition, astrocytes may contribute to the recovery of endothelial cells and neurite outgrowths since astrocytes also express neurotrophic factors and growth factors[50, 51]. Taken together, these observations suggest that monocytes may assist in regeneration of the brain microenvironment in the injured brain.

Conclusion

In the present study, impaired astrocytes, endothelial cells, and neurites were recovered, and myelination occurred, after monocytes had filled the lesion sites. We thus speculate that brain inflammation mediated by monocytes serves to repair damage in the injured brain. Our results highlight the physiological importance of brain inflammation in enhancing beneficial effects while minimizing harm.

Materials and methods

Ethics statement

All experiments were performed in accordance with the approved animal protocols and guidelines established by the Ajou University School of Medicine Ethics Review Committee, and all animal work was approved by the Ethical Committee for Animal Research of Ajou University (Amc-28).

Stereotaxic surgery and drug injection

Male Sprague–Dawley rats (230–250 g, 7 weeks old) were anesthetized by ketamine (40–80 mg/kg) and xylazine (5–10 mg/kg), and positioned in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). LPS (5 μg in 2 μl sterile PBS; Sigma, St. Louis, MO, USA) was unilaterally administered into the right SNpc (AP, -5.3 mm; ML, -2.3 mm; DV, -7.6 mm from the bregma), according to the atlas of Paxinos and Watson[52]. All animals were injected using a Hamilton syringe equipped with a 30-gauge blunt needle and attached to a syringe pump (KD Scientific, New Hope, PA, USA). LPS was infused at a rate of 0.4 μl/min. After injection, the needle was held in place for an additional 5 min before removal.

Tissue preparation

For immunostaining, rats were anesthetized and transcardially perfused with saline solution containing 0.5% sodium nitrate and heparin (10 U/ml), followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for tissue fixation. Brains were obtained and post-fixed overnight at 4°C in 4% paraformaldehyde. Fixed brains were stored at 4°C in a 30% sucrose solution until they sank. Six separate series of 30-μm coronal brain sections (50 μm for stereological counting) were obtained using a sliding microtome (Microm, Walldorf, Germany).

For RNA preparation, rats were anesthetized and transcardially perfused with saline solution without paraformaldehyde. Brains were obtained and sliced with a Rat Brain Slicer Matrix (1.0 mm slice intervals, RBM-4000C; ASI Instruments, Warren, MI, USA) and a razor blade. A slice that included the needle injection spot was selected, and tissue blocks (2 × 2 × 2 mm) just below the needle tip were collected and stored at −70°C until use.

Immunohistochemistry

For 3,3′-diaminobenzidine (DAB) staining, serial sections were rinsed three times with PBS, treated with 3% H2O2 for 5 min, and rinsed with PBS containing 0.2% Triton X-100 (PBST). Non-specific binding was blocked with 1% BSA in PBST. Sections were incubated overnight at room temperature with primary antibodies (Table 2). After rinsing in PBST, sections were incubated with biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA, USA) for 1 h and the avidin/biotin system (Vector Laboratories) for 1 h, and visualized using a DAB solution (0.05% DAB and 0.003% hydrogen peroxide in 0.1 M PB). Sections were then mounted on gelatin-coated slides and examined under a bright-field microscope (Olympus Optical, BX51, Tokyo, Japan). Bright-field images were obtained using PictureFrame Application 2.3 software. For immunofluorescence staining, sections were washed twice in PBS, treated with 1% BSA, and incubated with combinations of primary antibodies. For double-labeling, resident microglia and monocytes were stained for Iba-1, CD11b, or CD45 depending on the sources of antibodies against other proteins (Table 1). For visualization, Alexa Fluor 488- or Alexa Fluor 555-conjugated secondary antibodies (Invitrogen, Eugene, OR, USA) were used. DAPI (Vector Laboratories) was used to detect nuclei. Sections were analyzed under a confocal microscope (LSM 510, Carl Zeiss, Jena, Germany) with 40 × water- and 63 × oil-immersion objectives at 20°C. Images were captured using Confocal software (LSM Image Browser).
Table 2

Primary antibodies used in immunohistochemistry

Antibody

Source

Dilution

Catalogue no.

Company

APC (CC-1)

mouse

1:200

OP80

Calbiochem

CD11b

mouse

1:200

MCA275G

Serotec

CD45

mouse

1:200

MCA43R

Serotec

CD68

mouse

1:300

MCA341R

Serotec

EAAT1

rabbit

1:800

416

Abcam

GFAP

mouse

1:700

G3893

Sigma

Iba-1

rabbit

1:1000

019-19741

Wako

Ki-67

rabbit

1:200

AB9260

Chemicon

Kir4.1

rabbit

1:800

apc-035

Alomone

LAMP2

rabbit

1:200

L0668

Sigma

MAP2

mouse

1:1000

M4403

Sigma

MR

rabbit

1:200

ab64693

Abcam

Olig2

rabbit

1:200

OB-905

IBL

SMI 71

mouse

1:500

SMI-71R

Sternberger Monoclonals

S100β

rabbit

1:800

37

Swant

TH

rabbit

1:1000

P40101

Pel-Freeze

Vimentin

mouse

1:200

MAB3400

Chemicon

Reverse transcriptase-polymerase chain reaction (RT-PCR)

Total RNA was isolated using an easy-BLUE RNA Extraction Kit (iNtRON, Sungnam, Korea), and cDNA was prepared using Reverse Transcription Master Premix (ElpisBio, Daejeon, Korea), according to the manufacturers’ instructions. Approximately 100 ng cDNA was analyzed. The specific primers for TNF-α, iNOS, TGF-β, MR, and GAPDH used in RT-PCR are shown in Table 3. RT-PCR products were verified by electrophoresis on 1.5% agarose gels with GelRed (Biotium, Hayward, CA, USA) staining. GAPDH was used as a reference. Band intensities were analyzed using Quantity One 1-D analysis software, v 4.6.5 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Table 3

Primer sequences for RT-PCR

Gene

Sequence (5′-3′)

TNF-α

F: GTAGCCCACGTCGTAGCAAA

R: CCCTTCTCCAGCTGGGAGAC

iNOS

F: GCAGAATGTGACCATCATGG

R: ACAACCTTGGTGTTGAAGGC

TGF-β

F: GAGAGCCCTGGATACCAACTACTG

R: GTGTGTCCAGGCTCCAAATGTAG

MR

F: GTAGTTCTATCTTCATCTTC

R: AATATAAGACAGTCACATTA

GAPDH

F: TCCCTCAAGATTGTCAGCAA

R: AGATCCACAACGGATACATT

F Forward primer, R Reverse primer.

Microarray analysis

Sample preparation and labeling

Microarray experiments were performed in duplicate. For each sample, total RNA was extracted from tissue blocks (2 × 2 × 2 mm) obtained from four LPS-injected and uninjected rat brains using RNeasy mini kits (Qiagen GmbH, Hilden, Germany). Quantity and quality of RNA were assayed by UV spectrometry and RNA gel electrophoresis. RNA was labeled and hybridized to a GeneChip according to Standard Affymetrix Protocols (GeneChip Whole Transcript Sense Target Labeling Assay Manual, Version 4; Affymetrix, Santa Clara, CA). Affymetrix GeneChip Rat Gene 1.0 ST Arrays were used in this study. Each reaction involving a single GeneChip hybridization was initiated with 200 ng RNA. cDNA and cRNA were generated using a GeneChip WT cDNA Synthesis and Amplification Kit (900673, Affymetrix); cRNA cleanup was performed using a GeneChip IVT cRNA Cleanup Kit (900547, Affymetrix). After the second cDNA synthesis, cRNA was hydrolyzed by RNase H treatment, and biotin-labeled sense strand DNA fragments were generated using a GeneChip WT Terminal Labeling Kit (900671, Affymetrix).

Hybridization and scanning

Biotin-labeled DNA fragments (target) or controls in a hybridization cocktail were hybridized to the GeneChip array by incubating for 16 h in a GeneChip Hybridization Oven 640. Immediately following hybridization, the array was washed and stained with a streptavidin-phycoerythrin conjugate on the GeneChip Fluidics Station 450 using an automated protocol, followed by scanning on a GeneChip Scanner 3000 (7G). The GeneChip Hybridization, Wash, and Stain Kit (900720, Affymetrix) was used in this procedure.

Data measurement and analysis

An Affymetrix GeneChip scanner operated by GeneChip Operating Software (GCOS ver1.4; Affymetrix) was used to generate original array images. The average difference for each probe set (a measure of the relative abundance of a transcript) and signals and detection calls (i.e., present or absent) were computed using GCOS. Data were analyzed using Silicon Genetics Genespring 10.1 Software.

Eriochrome cyanine RC staining

Myelin was visualized with Eriochrome Cyanine RC (ECRC; Sigma). Brain sections were mounted on slides and air-dried overnight at room temperature. After dehydration and rehydration in graded ethanol solutions, sections were stained with ECRC solution (0.2% in 0.5% H2SO4) for 10 min, rinsed in running tap water, placed in 1% NH4OH for 30 s, and rinsed in distilled water. After dehydration, sections were treated with xylene and mounted using Permount (Fisher Scientific Co., Morris Plains, NJ, USA).

Measurement of damaged areas

Damaged areas were measured by staining every sixth brain section of the whole midbrain (AP, -4.3 to −6.5 mm from the bregma) with antibodies for specific markers of astrocytes (GFAP, S100β, EAAT1, and Kir4.1), endothelial cells (SMI 71), and neurites (MAP2). Myelin was stained with ECRC. Specific marker-negative areas in serial sections were measured on 4×-magnified images using Axiovision image-analysis software (version 4.7.2; Zeiss) and summed as shown in Additional file3: Figure S3.

Cell culture

Primary astrocytes were cultured from the cerebral cortices of 1-day-old Sprague–Dawley rats, as described previously[53, 54]. In brief, cortices were triturated in MEM (Sigma) containing 10% FBS (HyClone, Logan, UT, USA), plated in 75 cm2 T-flasks (0.5 hemisphere/flask), and incubated for 2–3 weeks. Microglia were removed from flasks by mild shaking, and astrocytes were cultured in serum-free MEM for 2–3 d. Astrocytes were harvested with 0.1% trypsin, plated, and cultured in MEM containing 10% FBS before use. Purity of astrocytes (>95%) was confirmed using GFAP antibodies.

Rat blood monocytes were isolated as described previously[55]. Briefly, blood was obtained by cardiac puncture and mixed with 2.5% dextran in PBS for 1 h at RT. The plasma layer was centrifuged at 300× g for 12 min. To remove red blood cells (RBC), the pellet was suspended in PBS containing 0.15 M NH4Cl, 10 mM NaHCO3, and 0.1 mM EDTA, and centrifuged at 350× g for 6 min. This process was repeated twice. Pellets containing monocytes and lymphocytes were suspended in PBS and placed in 15-ml polystyrene conical tubes (BD Falcon, NJ, USA). An equal volume of Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) was carefully added to the bottom of cell-containing tubes so as to prevent mixing with PBS. After centrifugation at 450× g for 30 min, cells between the Ficoll and PBS layers were collected, washed with PBS, suspended in HBSS containing calcium (140 mg/l), and plated in a Petri dish for 30 min. Unattached lymphocytes were removed and adherent monocytes were collected and cultured in MEM containing 10% FBS.

Astrocyte migration assay

Astrocyte migration was examined using a polydimethylsiloxane (PDMS) device[56] that was a gift from N. Jeon (Seoul National University). Briefly, PDMS device was comprised of two compartments. Each compartment had two reservoirs in the form of 8-mm-diameter holes, one at either end of the compartment, which served as a loading gate and medium reservoir, respectively (Figure 9A). The two holes in each compartment were connected by a main channel that was 1.5 mm wide, 100 μm high, and 7 mm in length. The two compartments were connected by 100 grooves, each 10 μm wide, 5 μm high, and 450 μm in length. Primary astrocytes (3 × 104 cells/125-150 μl for each hole) were plated in one compartment, and culture media (150 μl for each hole) was added to the other compartment. The following day, the media was removed from the media-filled compartment and then monocytes (2.5 × 104 cells/125-150 μl for each hole) were added to the compartment. The size of the grooves was sufficiently small that cells could not pass over to the opposite compartment during loading. The volume difference (50 μl) between compartments leads to convective flow from the higher volume side to the lower volume side. The difference in volume slowly decreased over time, but was still 10 μl at 7 d. Phase contrast images were taken every day and calcein AM-labeled fluorescence images were taken at 7 d using an AxioVision fluorescence light microscope (Zeiss Axiovert 200 M).

Statistical analysis

All values are expressed as means ± SEMs. The statistical significance of differences between mean values was assessed by Student’s t-test using the Statistical Package for Social Sciences 8.0 (SPSS Inc., Chicago, IL, USA).

Declarations

Acknowledgements

This work was supported by a KOSEF NRL Program grant (no. 2-2008025-0) funded by the Korean government (MEST), a grant (NRF-2012R1A5A2051429) from KOSEF through the Chronic Inflammatory Disease Research Center (CIDRC) at Ajou University, and a National Research Foundation of Korea Grant (NRF-2011-355-E00087) funded by the Korean Government (Ministry of Education, Science and Technology).

Authors’ Affiliations

(1)
Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine,Suwon, Kyunggi-do, 443-721, Korea
(2)
Department of Pharmacology, Ajou University School of Medicine, Suwon, Kyunggi-do, 443-721, Korea
(3)
National Research Lab of Brain inflammation, Ajou University School of Medicine, Suwon, Kyunggi-do, 443-721, Korea
(4)
Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon, Kyunggi-do, 443-721, Korea

References

  1. De Keyser J, Mostert JP, Koch MW: Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci. 2008, 267 (1–2): 3-16.View ArticlePubMedGoogle Scholar
  2. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005, 6 (12): 1191-1197. 10.1038/ni1276.View ArticlePubMedGoogle Scholar
  3. Stavitsky AB: The innate immune response to infection, toxins and trauma evolved into networks of interactive, defensive, reparative, regulatory, injurious and pathogenic pathways. Mol Immunol. 2007, 44 (11): 2787-2799. 10.1016/j.molimm.2007.01.011.View ArticlePubMedGoogle Scholar
  4. Oswald IP, Wynn TA, Sher A, James SL: Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A. 1992, 89 (18): 8676-8680. 10.1073/pnas.89.18.8676.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Wynn TA, Oswald IP, Eltoum IA, Caspar P, Lowenstein CJ, Lewis FA, James SL, Sher A: Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni. J Immunol. 1994, 153 (11): 5200-5209.PubMedGoogle Scholar
  6. Stein M, Keshav S, Harris N, Gordon S: Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J exper med. 1992, 176 (1): 287-292. 10.1084/jem.176.1.287.View ArticleGoogle Scholar
  7. Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.View ArticlePubMedGoogle Scholar
  8. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ: Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol. 2007, 170 (3): 818-829. 10.2353/ajpath.2007.060547.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8 (12): 958-969. 10.1038/nri2448.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Leibovich SJ, Ross R: The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol. 1975, 78 (1): 71-100.PubMed CentralPubMedGoogle Scholar
  11. Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis. 2005, 18 (1): 166-175. 10.1016/j.nbd.2004.09.019.View ArticlePubMedGoogle Scholar
  12. Ji KA, Yang MS, Jeong HK, Min KJ, Kang SH, Jou I, Joe EH: Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia. 2007, 55 (15): 1577-1588. 10.1002/glia.20571.View ArticlePubMedGoogle Scholar
  13. Ji KA, Eu MY, Kang SH, Gwag BJ, Jou I, Joe EH: Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia. 2008, 56 (10): 1039-1047. 10.1002/glia.20677.View ArticlePubMedGoogle Scholar
  14. Jeong HK, Ji KM, Kim B, Kim J, Jou I, Joe EH: Inflammatory responses are not sufficient to cause delayed neuronal death in ATP-induced acute brain injury. PLoS One. 2010, 5 (10): e13756-10.1371/journal.pone.0013756.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Min KJ, Jeong HK, Kim B, Hwang DH, Shin HY, Nguyen AT, Kim JH, Jou I, Kim BG, Joe EH: Spatial and temporal correlation in progressive degeneration of neurons and astrocytes in contusion-induced spinal cord injury. J neuroinflammation. 2012, 9 (1): 100-10.1186/1742-2094-9-100.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, Obrenovitch TP, Contreras TJ: Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke j cereb circulat. 1986, 17 (2): 246-253. 10.1161/01.STR.17.2.246.View ArticleGoogle Scholar
  17. Matsumoto H, Kumon Y, Watanabe H, Ohnishi T, Shudou M, Ii C, Takahashi H, Imai Y, Tanaka J: Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions. J Neurosci Res. 2007, 85 (5): 994-1009. 10.1002/jnr.21198.View ArticlePubMedGoogle Scholar
  18. De Pablos RM, Herrera AJ, Villaran RF, Cano J, Machado A: Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB j off publ Federat Am Soc Exper Biol. 2005, 19 (3): 407-409.Google Scholar
  19. Marshall CA, Novitch BG, Goldman JE: Olig2 directs astrocyte and oligodendrocyte formation in postnatal subventricular zone cells. J neurosci offi j Soc Neurosci. 2005, 25 (32): 7289-7298. 10.1523/JNEUROSCI.1924-05.2005.View ArticleGoogle Scholar
  20. Chen Y, Miles DK, Hoang T, Shi J, Hurlock E, Kernie SG, Lu QR: The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury. J neurosci off j Soc Neurosci. 2008, 28 (43): 10983-10989. 10.1523/JNEUROSCI.3545-08.2008.View ArticleGoogle Scholar
  21. Akiyama H, McGeer PL: Brain microglia constitutively express beta-2 integrins. J Neuroimmunol. 1990, 30 (1): 81-93. 10.1016/0165-5728(90)90055-R.View ArticlePubMedGoogle Scholar
  22. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S: A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun. 1996, 224 (3): 855-862. 10.1006/bbrc.1996.1112.View ArticlePubMedGoogle Scholar
  23. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S: Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain res Mol brain res. 1998, 57 (1): 1-9. 10.1016/S0169-328X(98)00040-0.View ArticlePubMedGoogle Scholar
  24. Campanella M, Sciorati C, Tarozzo G, Beltramo M: Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke j cereb circulat. 2002, 33 (2): 586-592. 10.1161/hs0202.103399.View ArticleGoogle Scholar
  25. Aderem A, Underhill DM: Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999, 17: 593-623. 10.1146/annurev.immunol.17.1.593.View ArticlePubMedGoogle Scholar
  26. Astarie-Dequeker C, N’Diaye EN, Le Cabec V, Rittig MG, Prandi J, Maridonneau-Parini I: The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect Immun. 1999, 67 (2): 469-477.PubMed CentralPubMedGoogle Scholar
  27. da Silva RP, Gordon S: Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J. 1999, 338 (Pt 3): 687-694.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S: LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007, 26 (2): 313-324. 10.1038/sj.emboj.7601511.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Ivaska J, Pallari HM, Nevo J, Eriksson JE: Novel functions of vimentin in cell adhesion, migration, and signaling. Exper cell res. 2007, 313 (10): 2050-2062. 10.1016/j.yexcr.2007.03.040.View ArticleGoogle Scholar
  30. Wang K, Bekar LK, Furber K, Walz W: Vimentin-expressing proximal reactive astrocytes correlate with migration rather than proliferation following focal brain injury. Brain res. 2004, 1024 (1–2): 193-202.View ArticlePubMedGoogle Scholar
  31. Yang MS, Min KJ, Joe E: Multiple mechanisms that prevent excessive brain inflammation. J Neurosci Res. 2007, 85 (11): 2298-2305. 10.1002/jnr.21254.View ArticlePubMedGoogle Scholar
  32. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB: ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005, 8 (6): 752-758. 10.1038/nn1472.View ArticlePubMedGoogle Scholar
  33. D’Mello C, Le T, Swain MG: Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J neurosci off j Soc Neurosci. 2009, 29 (7): 2089-2102. 10.1523/JNEUROSCI.3567-08.2009.View ArticleGoogle Scholar
  34. Pyo H, Yang MS, Jou I, Joe EH: Wortmannin enhances lipopolysaccharide-induced inducible nitric oxide synthase expression in microglia in the presence of astrocytes in rats. Neurosci Lett. 2003, 346 (3): 141-144. 10.1016/S0304-3940(03)00505-6.View ArticlePubMedGoogle Scholar
  35. Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J: Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia. 2004, 46 (4): 369-379. 10.1002/glia.20009.View ArticlePubMedGoogle Scholar
  36. Min KJ, Yang MS, Kim SU, Jou I, Joe EH: Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J neurosci off j Soc Neurosci. 2006, 26 (6): 1880-1887. 10.1523/JNEUROSCI.3696-05.2006.View ArticleGoogle Scholar
  37. Kim JH, Min KJ, Seol W, Jou I, Joe EH: Astrocytes in injury states rapidly produce anti-inflammatory factors and attenuate microglial inflammatory responses. J Neurochem. 2010, 115 (5): 1161-1171. 10.1111/j.1471-4159.2010.07004.x.View ArticlePubMedGoogle Scholar
  38. Kim B, Jeong HK, Kim JH, Lee SY, Jou I, Joe EH: Uridine 5′-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. J Immunol. 2011, 186 (6): 3701-3709. 10.4049/jimmunol.1000212.View ArticlePubMedGoogle Scholar
  39. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H: TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS med. 2007, 4 (4): e124-10.1371/journal.pmed.0040124.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD: Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebros fluid res. 2008, 5: 10-10.1186/1743-8454-5-10.View ArticleGoogle Scholar
  41. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998, 101 (4): 890-898. 10.1172/JCI1112.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Brandt E, Woerly G, Younes AB, Loiseau S, Capron M: IL-4 production by human polymorphonuclear neutrophils. J Leukoc Biol. 2000, 68 (1): 125-130.PubMedGoogle Scholar
  43. Cassiani-Ingoni R, Coksaygan T, Xue H, Reichert-Scrivner SA, Wiendl H, Rao MS, Magnus T: Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation. Exp Neurol. 2006, 201 (2): 349-358. 10.1016/j.expneurol.2006.04.030.View ArticlePubMedGoogle Scholar
  44. Magnus T, Coksaygan T, Korn T, Xue H, Arumugam TV, Mughal MR, Eckley DM, Tang SC, Detolla L, Rao MS, et al: Evidence that nucleocytoplasmic Olig2 translocation mediates brain-injury-induced differentiation of glial precursors to astrocytes. J Neurosci Res. 2007, 85 (10): 2126-2137. 10.1002/jnr.21368.View ArticlePubMedGoogle Scholar
  45. Comabella M, Imitola J, Weiner HL, Khoury SJ: Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol. 2002, 126 (1–2): 205-212.View ArticlePubMedGoogle Scholar
  46. Sabbatucci M, Purificato C, Fantuzzi L, Gessani S: Toll-like receptor cross-talk in human monocytes regulates CC-chemokine production, antigen uptake and immune cell recruitment. Immunobiology. 2011, 216 (10): 1135-1142. 10.1016/j.imbio.2011.04.005.View ArticlePubMedGoogle Scholar
  47. Martinet Y, Bitterman PB, Mornex JF, Grotendorst GR, Martin GR, Crystal RG: Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature. 1986, 319 (6049): 158-160. 10.1038/319158a0.View ArticlePubMedGoogle Scholar
  48. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB: Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA. 1987, 84 (17): 6020-6024. 10.1073/pnas.84.17.6020.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Molnarfi N, Benkhoucha M, Bjarnadóttir K, Juillard C, Lalive PH: Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients. PLoS One. 2012, 7 (11): e49882-10.1371/journal.pone.0049882.PubMed CentralView ArticlePubMedGoogle Scholar
  50. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW: Pro-regenerative properties of cytokine-activated astrocytes. J Neurochem. 2004, 89 (5): 1092-1100. 10.1111/j.1471-4159.2004.02420.x.View ArticlePubMedGoogle Scholar
  51. Scott A, Powner MB, Gandhi P, Clarkin C, Gutmann DH, Johnson RS, Ferrara N, Fruttiger M: Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS One. 2010, 5 (7): e11863-10.1371/journal.pone.0011863.PubMed CentralView ArticlePubMedGoogle Scholar
  52. Paxinos G, Watson CR: The rat brain in stereotaxic coordinates. 2005, Amsterdam; Boston: Elsevier Academic Press, 5Google Scholar
  53. Giulian D, Baker TJ: Characterization of ameboid microglia isolated from developing mammalian brain. J neurosci off j Soci Neurosci. 1986, 6 (8): 2163-2178.Google Scholar
  54. Pyo H, Jou I, Jung S, Hong S, Joe EH: Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport. 1998, 9 (5): 871-874. 10.1097/00001756-199803300-00020.View ArticlePubMedGoogle Scholar
  55. Lehner M, Holter W: Endotoxin-free purification of monocytes for dendritic cell generation via discontinuous density gradient centrifugation based on diluted Ficoll-Paque Plus. Int archives allergy immunol. 2002, 128 (1): 73-76. 10.1159/000058006.View ArticleGoogle Scholar
  56. Park JW, Vahidi B, Taylor AM, Rhee SW, Jeon NL: Microfluidic culture platform for neuroscience research. Nat Protoc. 2006, 1 (4): 2128-2136. 10.1038/nprot.2006.316.View ArticlePubMedGoogle Scholar

Copyright

© Jeong et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Molecular Brain

ISSN: 1756-6606